1
|
Ahmadi A, Min J, Berger A, Achenbach S,
Alaamri S, Al-Mallah M, Berman D, Budoff M, Cademartiri F,
Callister T, et al: Does prognosis change depending on number and
composition of non obstructive plaques? Results from the
multinational coronary CT angiography evaluation for clinical
outcome: An international multicenter registry (CONFIRM). J Am Coll
Cardiol. 63(A980)2014.
|
2
|
Holman RR, Coleman RL, Chan JCN, Chiasson
J-L, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, et al: ACE
Study Group: Effects of acarbose on cardiovascular and diabetes
outcomes in patients with coronary heart disease and impaired
glucose tolerance (ACE): A randomised, double-blind,
placebo-controlled trial. Lancet Diabetes Endocrinol. 5:877–886.
2017.PubMed/NCBI View Article : Google Scholar
|
3
|
Li H, Sun K, Zhao R, Hu J, Hao Z, Wang F,
Lu Y, Liu F and Zhang Y: Inflammatory biomarkers of coronary heart
disease. Front Biosci. 22:504–515. 2017.PubMed/NCBI View
Article : Google Scholar
|
4
|
Brown AJ, Shah ASV, West NEJ, Costopoulos
C, Orzalkiewicz M, Newby DE, Bennett MR, Mills NL and Calvert PA:
High-Sensitivity Troponin I Is Associated With High-Risk Plaque and
MACE in Stable Coronary Artery Disease. JACC Cardiovasc Imaging.
10A:A1200–A1203. 2017.PubMed/NCBI View Article : Google Scholar
|
5
|
Loria V, Dato I, Graziani F and Biasucci
LM: Myeloperoxidase: A new biomarker of inflammation in ischemic
heart disease and acute coronary syndromes. Mediators Inflamm.
2008:135625. 2008.PubMed/NCBI View Article : Google Scholar
|
6
|
Masud R and Baqai HZ: The communal
relation of MTHFR, MTR, ACE gene polymorphisms and
hyperhomocysteinemia as conceivable risk of coronary artery
disease. Appl Physiol Nutr Metab. 42:1009–1014. 2017.PubMed/NCBI View Article : Google Scholar
|
7
|
Karolczak K, Kubalczyk P, Glowacki R,
Pietruszynski R and Watala C: Aldosterone modulates blood
homocysteine and cholesterol in coronary artery disease patients -
a possible impact on atherothrombosis? Physiol Res. 67:197–207.
2018.PubMed/NCBI View Article : Google Scholar
|
8
|
Tayefi M, Tajfard M, Saffar S, Hanachi P,
Amirabadizadeh AR, Esmaeily H, Taghipour A, Ferns GA, Moohebati M
and Ghayour-Mobarhan M: hs-CRP is strongly associated with coronary
heart disease (CHD): A data mining approach using decision tree
algorithm. Comput Methods Programs Biomed. 141:105–109.
2017.PubMed/NCBI View Article : Google Scholar
|
9
|
Nortamo S, Ukkola O, Lepojärvi S, Kenttä
T, Kiviniemi A, Junttila J, Huikuri H and Perkiömäki J: Association
of sST2 and hs-CRP levels with new-onset atrial fibrillation in
coronary artery disease. Int J Cardiol. 248:173–178.
2017.PubMed/NCBI View Article : Google Scholar
|
10
|
Rifaie O, Ahmed Abdel-Rahman M and Mabrouk
Salem Omar A: Favorable inflammatory status following intermittent
fasting in patients with atherosclerotic coronary heart disease
after revascuralization. Eur Heart J. 34 (Suppl 1)(P5502)2013.
|
11
|
Yang K, Dong G, Tian Y and Li J: Effects
of compound Danshen injection combined with magnesium sulfate on
serum MPO and hs-CRP in patients with severe preeclampsia. Exp Ther
Med. 16:167–170. 2018.PubMed/NCBI View Article : Google Scholar
|
12
|
Liu C, Chen L, Yang Y, Huang C, Luo J and
Peng D: Myeloperoxidase and high-sensitivity C-reactive protein for
predicting major adverse cardiovascular events in patients with
coronary heart disease. Int J Clin Med. 6:262–270. 2015.
|
13
|
Nurkalem Z, Hasdemir H, Ergelen M, Aksu H,
Sahin I, Erer B, Yilmaz HY, Comert N, Sargin M and Eren M: The
relationship between glucose tolerance and severity of coronary
artery disease using the Gensini score. Angiology. 61:751–755.
2010.PubMed/NCBI View Article : Google Scholar
|
14
|
Zhao W, Rasheed A, Tikkanen E, Lee J-J,
Butterworth AS, Howson JMM, Assimes TL, Chowdhury R, Orho-Melander
M, Damrauer S, et al: CHD Exome+ Consortium; EPIC-CVD Consortium;
EPIC-Interact Consortium; Michigan Biobank: Identification of new
susceptibility loci for type 2 diabetes and shared etiological
pathways with coronary heart disease. Nat Genet. 49:1450–1457.
2017.PubMed/NCBI View
Article : Google Scholar
|
15
|
Lee JH, Han D, Hartaigh BÓ, Gransar H, Lu
Y, Rizvi A, Park MW, Roudsari HM, Stuijfzand WJ, Berman DS, et al:
Influence of symptom typicality for predicting MACE in patients
without obstructive coronary artery disease: From the CONFIRM
Registry (Coronary Computed Tomography Angiography Evaluation for
Clinical Outcomes: An International Multicenter Registry). Clin
Cardiol. 41:586–593. 2018.PubMed/NCBI View Article : Google Scholar
|
16
|
Hashemian M, Poustchi H,
Mohammadi-Nasrabadi F and Hekmatdoost A: Systematic review of zinc
biochemical indicators and risk of coronary heart disease. ARYA
Atheroscler. 11:357–365. 2015.PubMed/NCBI
|
17
|
Luyao C, Shushan Z, Ruizheng S and Guogang
Z: GW24-e0526 The Relationship Between MPO-463 G/A, MPO-129 G/A
Gene Polymorphism and Coronary Heart Disease: A Meta-Analysis.
Heart. 99 (Suppl 3):A117–A118. 2013.
|
18
|
Hu J, Xu J, Zhou X, Jiang T, Li Y and
Zhang M: Correlation between MPO 129 A/G polymorphism and severity
of coronary artery disease. Zhongguo Ying Yong Sheng Li Xue Za Zhi.
27:306–310. 2011.PubMed/NCBI
|
19
|
Bjørnestad EØ, Borsholm RA, Svingen GFT,
Pedersen ER, Seifert R, Midttun Ø, Ueland PM, Tell GS, Bønaa KH and
Nygård O: Neopterin as an Effect Modifier of the Cardiovascular
Risk Predicted by Total Homocysteine: A Prospective 2-Cohort Study.
J Am Heart Assoc. 6(e006500)2017.PubMed/NCBI View Article : Google Scholar
|
20
|
Wang L-Y, Zhang H-L and Chen S: Effect of
atorvastatin combined with trimetazidine on oxidative stress,
hemorheology and NT-proBNP, hs-CRP in patients with coronary heart
disease. Hainan Yixueyuan Xuebao. 23:2323–2327. 2017.
|
21
|
Fong SW, Few LL, See Too WC, Khoo BY, Nik
Ibrahim NN, Yahaya SA, Yusof Z, Mohd Ali R, Abdul Rahman AR and
Yvonne-Tee GB: Systemic and coronary levels of CRP, MPO, sCD40L and
PlGF in patients with coronary artery disease. BMC Res Notes.
8(679)2015.PubMed/NCBI View Article : Google Scholar
|
22
|
Karakas M, Koenig W, Zierer A, Herder C,
Rottbauer W, Baumert J, Meisinger C and Thorand B: Myeloperoxidase
is associated with incident coronary heart disease independently of
traditional risk factors: Results from the MONICA/KORA Augsburg
study. J Intern Med. 271:43–50. 2012.PubMed/NCBI View Article : Google Scholar
|
23
|
Mansori K and Ayubi E: Comments on
association of sST2 and hs-CRP levels with new-onset atrial
fibrillation in coronary artery disease. Int J Cardiol.
257(32)2018.PubMed/NCBI View Article : Google Scholar
|
24
|
Zhang X, Dong L, Wang Q and Xie X: The
relationship between fasting plasma glucose and MPO in patients
with acute coronary syndrome. BMC Cardiovasc Disord.
15(93)2015.PubMed/NCBI View Article : Google Scholar
|
25
|
Huang X, Lv X, Song H, Yang Q, Sun Y,
Zhang W, Yu X, Dong S, Yao W, Li Y, et al: The relationship between
S-adenosylhomocysteine and coronary artery lesions: A case control
study. Clin Chim Acta. 471:314–320. 2017.PubMed/NCBI View Article : Google Scholar
|
26
|
Szalai AJ, McCrory MA, Xing D, Hage FG,
Miller A, Oparil S, Chen Y-F, Mazzone M, Early R, Henry SP, et al:
Inhibiting C-reactive protein for the treatment of cardiovascular
disease: promising evidence from rodent models. Mediators Inflamm.
2014(353614)2014.PubMed/NCBI View Article : Google Scholar
|
27
|
Li S, Jiao Y, Wang H, Shang Q, Lu F, Huang
L, Liu J, Xu H and Chen K: Sodium tanshinone IIA sulfate adjunct
therapy reduces high-sensitivity C-reactive protein level in
coronary artery disease patients: A randomized controlled trial.
Sci Rep. 7(17451)2017.PubMed/NCBI View Article : Google Scholar
|
28
|
Abhashi SA, Kryeziu FU and Nazreku FD:
Increased carotid intima-media thickness associated with high
hs-CRP levels is a predictor of unstable coronary artery disease.
Cardiovasc J Afr. 24:270–273. 2013.PubMed/NCBI View Article : Google Scholar
|
29
|
Tajfard M, Tavakoly Sany SB, Avan A,
Latiff LA, Rahimi HR, Moohebati M, Hasanzadeh M, Ghazizadeh H,
Esmaeily H, Doosti H, et al: Relationship between serum high
sensitivity C-reactive protein with angiographic severity of
coronary artery disease and traditional cardiovascular risk
factors. J Cell Physiol. 234:10289–10299. 2019.PubMed/NCBI View Article : Google Scholar
|
30
|
Emami Razavi A, Basati G, Varshosaz J and
Abdi S: Association between HDL particles size and myeloperoxidase/
paraoxonase-1 (MPO/PON1) ratio in patients with acute coronary
syndrome. Acta Med Iran. 51:365–371. 2013.PubMed/NCBI
|
31
|
Kaya mg, Yalcin R, Okyay K, Poyraz F,
Bayraktar N, Pasaoglu H, Boyaci B and Cengel A: Potential role of
plasma myeloperoxidase level in predicting long-term outcome of
acute myocardial infarction. Tex Heart Inst J. 39:500–506.
2012.PubMed/NCBI
|
32
|
Tang WH, Shrestha K, Troughton RW,
Borowski AG and Klein AL: Integrating plasma high-sensitivity
C-reactive protein and myeloperoxidase for risk prediction in
chronic systolic heart failure. Congest Heart Fail. 17:105–109.
2011.PubMed/NCBI View Article : Google Scholar
|
33
|
Cho D-Y, Kim K-N, Kim K-M, Lee D-J and Kim
B-T: Combination of high-sensitivity C-reactive protein and
homocysteine may predict an increased risk of coronary artery
disease in Korean population. Chin Med J (Engl). 125:569–573.
2012.PubMed/NCBI
|